CN107073016A - 用于治疗肥胖症的雷公藤红素和衍生物 - Google Patents

用于治疗肥胖症的雷公藤红素和衍生物 Download PDF

Info

Publication number
CN107073016A
CN107073016A CN201580027586.3A CN201580027586A CN107073016A CN 107073016 A CN107073016 A CN 107073016A CN 201580027586 A CN201580027586 A CN 201580027586A CN 107073016 A CN107073016 A CN 107073016A
Authority
CN
China
Prior art keywords
ether
alkyl
ester
amine
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580027586.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·马兹斯柴克
U·奥兹坎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Priority to CN202311282376.1A priority Critical patent/CN117357538A/zh
Publication of CN107073016A publication Critical patent/CN107073016A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C62/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C62/30—Unsaturated compounds
    • C07C62/38—Unsaturated compounds containing keto groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CN201580027586.3A 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物 Pending CN107073016A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311282376.1A CN117357538A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970839P 2014-03-26 2014-03-26
US61/970,839 2014-03-26
PCT/US2015/022746 WO2015148802A1 (en) 2014-03-26 2015-03-26 Celastrol and derivatives for the treatment of obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311282376.1A Division CN117357538A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Publications (1)

Publication Number Publication Date
CN107073016A true CN107073016A (zh) 2017-08-18

Family

ID=52823863

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202311282376.1A Pending CN117357538A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物
CN201580027586.3A Pending CN107073016A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202311282376.1A Pending CN117357538A (zh) 2014-03-26 2015-03-26 用于治疗肥胖症的雷公藤红素和衍生物

Country Status (10)

Country Link
US (3) US20150274634A1 (enExample)
EP (1) EP3122347B1 (enExample)
JP (1) JP2017513824A (enExample)
CN (2) CN117357538A (enExample)
AU (2) AU2015235979B2 (enExample)
BR (1) BR112016021985B1 (enExample)
CA (2) CA3044998A1 (enExample)
ES (1) ES2813424T3 (enExample)
RU (1) RU2706239C2 (enExample)
WO (1) WO2015148802A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821308A (zh) * 2019-04-15 2020-10-27 中国科学院上海药物研究所 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用
CN115023431A (zh) * 2019-09-12 2022-09-06 藤济(厦门)生物医药科技有限公司 三萜类化合物，其药物组合物和在治疗核受体亚家族4组成员1所介导疾病中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2209911B1 (en) 2007-10-19 2013-10-16 The Trustees of Columbia University in the City of New York Dna sequencing with non-fluorescent nucleotide reversible terminators and cleavable label modified nucleotide terminators and a deoxyinosine analogue with a reversible terminator group
US20170209408A1 (en) * 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
JP7034078B2 (ja) 2015-10-23 2022-03-11 イーアールエックス ファーマシューティカルズ インコーポレイテッド セラストロールの類似体
US10053693B2 (en) 2016-01-19 2018-08-21 Mubin I. Syed Method for controlling obesity using minimally invasive means
US11446265B2 (en) 2016-06-15 2022-09-20 Targa Biomedical Reagents, compositions and methods for improving viability and function of cells, tissues and organs
JP2019523245A (ja) * 2016-07-04 2019-08-22 厦▲門▼大学 オーファン核内受容体Ｎｕｒ７７のリガンド及びその使用
CN106243181A (zh) * 2016-07-29 2016-12-21 合肥中科玛卡生物技术有限公司 一种从苦瓜中提取雷公藤红素的方法
US20200000752A1 (en) * 2016-08-03 2020-01-02 Vanderbilt University Method for Treating Epilepsy
CN117860904B (zh) * 2024-01-10 2025-02-18 四川大学 一种四面体框架核酸-雷公藤红素复合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101434635A (zh) * 2007-11-16 2009-05-20 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
JP2006508182A (ja) * 2002-10-21 2006-03-09 メタプロテオミクス， エルエルシー 炎症応答と関連した病理学的状態を処置または抑制する組成物。
JP4169777B2 (ja) * 2005-09-30 2008-10-22 森永乳業株式会社 インスリン抵抗性改善剤
CN101686951A (zh) * 2006-11-13 2010-03-31 纽约市哥伦比亚大学托管会 治疗糖尿病的选择性蛋白酶体抑制物
US8641155B2 (en) * 2007-07-26 2014-02-04 David Lee Modular furniture system
US7776894B2 (en) * 2007-08-17 2010-08-17 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
CA2712593A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CA2808359C (en) * 2010-08-23 2019-09-24 Suzhou Neupharma Co., Ltd. Analogs of celasterol and pharmaceutical compositions comprised thereof
KR102033190B1 (ko) * 2012-01-20 2019-10-16 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 헤테로시클릭 아미드 유도체
HK1209035A1 (en) * 2012-05-25 2016-03-24 Berg Llc Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
CN111529534A (zh) * 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
CN103524592B (zh) * 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101434635A (zh) * 2007-11-16 2009-05-20 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JI EUN LEE等: "The Effect of Celastrol on Metabolic Disturbances and Renal Injury in High Fat Diet-induced Obesity Mice", 《THE KOREAN JOURNAL OF NEPHROLOGY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111821308A (zh) * 2019-04-15 2020-10-27 中国科学院上海药物研究所 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用
CN111821308B (zh) * 2019-04-15 2021-10-08 中国科学院上海药物研究所 雷藤舒在制备用于治疗非酒精性脂肪性肝病的药物中的应用
CN115023431A (zh) * 2019-09-12 2022-09-06 藤济(厦门)生物医药科技有限公司 三萜类化合物，其药物组合物和在治疗核受体亚家族4组成员1所介导疾病中的用途
CN115023431B (zh) * 2019-09-12 2024-02-02 藤济(厦门)生物医药科技有限公司 三萜类化合物，其药物组合物和在治疗核受体亚家族4组成员1所介导疾病中的用途

Also Published As

Publication number Publication date
CA2944030A1 (en) 2015-10-01
RU2706239C2 (ru) 2019-11-15
CN117357538A (zh) 2024-01-09
EP3122347A1 (en) 2017-02-01
BR112016021985A8 (pt) 2021-06-29
BR112016021985A2 (pt) 2017-08-15
BR112016021985B1 (pt) 2022-08-30
AU2015235979A1 (en) 2016-10-20
AU2015235979B2 (en) 2019-05-02
EP3122347B1 (en) 2020-06-03
US20150274634A1 (en) 2015-10-01
US20190062254A1 (en) 2019-02-28
US20180194709A1 (en) 2018-07-12
WO2015148802A1 (en) 2015-10-01
ES2813424T3 (es) 2021-03-23
RU2016141567A3 (enExample) 2018-04-27
CA3044998A1 (en) 2015-10-01
AU2019202601A1 (en) 2019-05-02
RU2016141567A (ru) 2018-04-27
CA2944030C (en) 2019-06-04
JP2017513824A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
US11045439B2 (en) Compounds for the treatment of obesity and methods of use thereof
CN107073016A (zh) 用于治疗肥胖症的雷公藤红素和衍生物
HK40083451A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034040A (en) Compounds for the treatment of obesity and methods of use thereof
HK40034039A (en) Compounds for the treatment of obesity and methods of use thereof
HK1233923B (en) Celastrol derivatives for the treatment of obesity
HK1233923A1 (en) Celastrol derivatives for the treatment of obesity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20190806

Address after: Massachusetts, USA

Applicant after: CHILDREN'S MEDICAL CENTER Corp.

Applicant after: THE GENERAL Hospital Corp.

Address before: Massachusetts, USA

Applicant before: Children's Medical Center Corp.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20170818

RJ01 Rejection of invention patent application after publication